February 20, 2018 12:35 PM EST
R&D
Pharma

Take­da com­mits to a $230M pack­age to seal block­buster neu­ro­log­i­cal R&D deal with Wave Life Sci­ences

Brittany Meiling

Biotech gi­ant Take­da is en­ter­ing a mega-sized part­ner­ship with Wave Life Sci­ences, a Cam­bridge, Mass­a­chu­setts-based com­pa­ny, to work on a se­ries of pro­grams for neu­ro­log­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times